Key regions: Australia, Germany, United Kingdom, United States, France
The market for Immunosuppressants in Central Asia has been growing steadily over the past few years, driven by several key factors.
Customer preferences: Patients in Central Asia suffering from autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus have been increasingly opting for immunosuppressant drugs as a means of managing their symptoms. This trend is in line with global market trends, as the prevalence of autoimmune diseases continues to rise worldwide.
Trends in the market: One of the key trends in the Immunosuppressants market in Central Asia is the growing popularity of biologic drugs. These drugs, which are derived from living organisms, have proven to be highly effective in treating autoimmune diseases, and are increasingly being prescribed by doctors in the region. Another trend is the increasing availability of generic immunosuppressants, which are more affordable than their branded counterparts and are therefore more accessible to patients.
Local special circumstances: One factor that has helped to drive the growth of the Immunosuppressants market in Central Asia is the relatively low cost of healthcare in the region. This has made it easier for patients to access the drugs they need, and has also helped to stimulate demand for immunosuppressants. Additionally, the region's aging population has also contributed to the growth of the market, as older people are more likely to suffer from autoimmune diseases.
Underlying macroeconomic factors: Several macroeconomic factors have also contributed to the growth of the Immunosuppressants market in Central Asia. These include the region's growing middle class, which has more disposable income to spend on healthcare, as well as the increasing prevalence of autoimmune diseases. Additionally, the region's improving healthcare infrastructure has also helped to drive the growth of the market, as more patients are able to access the drugs they need.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
